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Abstract The objectives of this study are to explore the
causes of permanent discontinuation of biological therapies
in inflammatory rheumatic diseases and to analyse the subse-
quent course of the disease activity. In this multi-centre retro-
spective cohort study, data on 126 rheumatoid arthritis, 38
ankylosing spondylitis and 11 psoriatic arthritis patients were
analysed, in whom biological therapies had been permanently
discontinued. The reasons for the cessation of biologics, the
DAS28 or BASDAI disease activity indices at the time of
discontinuation and thereafter, and the subsequent occurrence
of relapses and the duration of remission or low disease
activity were investigated. The most common causes of dis-
continuation were adverse events (45 %), inefficacy (16 %) or
remission (10 %). In rheumatoid arthritis, 33.3 % remained in
low disease activity after a mean follow-up of 22 months. If
the biologic was stopped when the disease was inactive,
60.6 % remained inactive, and in all the patients in whom
the biologic was discontinued because of long-standing re-
mission, the disease remained inactive. Predictors of remis-
sion after discontinuation were low disease activity at stop-
ping the biologic and shorter duration of biological therapy. In
contrast, 50 % of the ankylosing spondylitis patients relapsed
after the withdrawal of anti-TNF therapy. Biologic-free low
disease activity can be achieved in at least one third of rheu-
matoid arthritis patients, and low disease activity at the time of
discontinuation is a strong predictor of a subsequent
favourable disease course. The likelihood of continued remis-
sion after the cessation of a biological therapy is much lower
in ankylosing spondylitis.
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Introduction
The introduction of biological therapies including tumour
necrosis factor-α (TNF-α) inhibitors, interleukin-6 receptor
blockers, B cell-depleting antibodies and costimulation
blockers into the treatment of inflammatory rheumatic dis-
eases in recent years has led to a complete renewal of treat-
ment goals and therapeutic paradigms. The indications of the
initiation of biological therapies have been thoroughly
characterised and have been implemented in international
and national practice guidelines [1]. However, with the rapidly
increasing number of patients on biological therapies and of
those who have achieved a long-term remission or low disease
activity (LDA) with these agents, the issues of how long
biologics should be administered and whether the discontinu-
ation of these drugs can be achieved have gained increasing
attention [2]. Potential concerns about the adverse effects and
the high costs of long treatment courses also necessitate pre-
cise answers to these questions.
The 2010 European League Against Rheumatism
(EULAR) recommendations about the treatment of rheuma-
toid arthritis (RA) suggest that once a sustained remission has
been achieved, first the glucocorticoid therapy should be
tapered off, and the discontinuation of a biologic disease-
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modifying anti-rheumatic drug (DMARD) may subsequently
be attempted. However, these guidelines have not yet been
corroborated by firm evidence. The risk of flares after the
cessation of an effective therapy and the uncertainty of wheth-
er these treatments may be re-introduced successfully also
need to be elucidated. Few studies that have been specifically
designed to measure the disease activity and radiographic
progression in RA after the discontinuation of biologic
DMARDs have suggested that long-term biologic-free or
even drug-free remission may be achieved in some patients
[3–9]. However, predictors of a sustained remission have not
been conclusively identified, and the proportions of these
patients are variable across the studies; furthermore, only very
limited knowledge exists about the disease course after the
discontinuation of anti-TNF therapy in ankylosing spondylitis
(AS) [10, 11] and psoriatic arthritis (PsA).
In this retrospective, multi-centre observational study, our
aims were to explore the causes of discontinuation of biolog-
ical therapies in RA, AS and PsA in the practice of three
arthritis centres in Hungary and to analyse the subsequent
disease course. We assessed the frequencies of relapses, the
duration of remission or LDA and attempted to identify pre-
dictors of a sustained remission after the cessation of
biologics.
Methods
The studied patient population consisted of RA, AS or PsA
patients treated with biological therapies in Szeged, Debrecen
and Gyula, three tertiary arthritis referral centres in southern
and eastern Hungary, together serving for a population of
approximately 1.5 million people. The protocol was approved
by the appropriate ethics committee and has therefore been
performed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki and its later amendments.
All patients had been treated with biological therapies (anti-
TNF, the IL-6 receptor blocker tocilizumab or the anti-CD20
monoclonal antibody rituximab) in accordancewith the guide-
lines by the Hungarian Board of Rheumatologists, which is an
adaptation of the EULAR recommendations. RA and periph-
eral PsA patients had failed a combination of two traditional
DMARDs, and AS and axial PsA patients had a highly active
disease despite the treatment with at least two non-steroidal
anti-inflammatory agents before biologics were initiated. Pa-
tients were enrolled in the present investigation if the treating
physician decided that the administration of biological therapy
is discontinued permanently or until an indefinite time. One-
hundred twenty-six patients with RA, 38 with AS and 11 with
PsA met these criteria, making a total of 175 patients for the
assessment of the causes of discontinuation. These patients
constitute 13.7 % (RA), 9.3 % (AS) and 11.2 % (PsA) of the
total cohort of biologic-treated patients, respectively. The
decision of stopping the biologic was made after a mean of
20 months (RA), 13 months (AS) and 9 months (PsA) of
treatment.
The mean age of the patients was 60 years (21–84) in RA,
46 years (20–67) in AS and 57 years (24–74) in PsA. Sixty-
eight percent of the RA patients were anti-citrullinated peptide
(ACPA) positive, 66.9 %were rheumatoid factor positive, and
radiographic erosions were detected in 58 %. The causes of
discontinuation were categorised as adverse event or allergic
reaction (severe or repeated), chronic or recurrent infections,
the presence or the suspicion of tumour, long-term remission,
family planning and inefficacy or insufficient compliance.
After the cessation of the biological therapy, follow-up data
were available in 81 RA, 17AS and 2 PsA patients. Follow-up
data were, therefore, evaluated only in RA and AS (a total of
98 patients). In RA, we considered the disease of low activity
when Disease Activity Score 28 (DAS28) is <3.2, whereas
high activity was defined as DAS28>5.1. Although remission
(DAS28<2.6) has been attained by many of the patients, as
the patient population consisted mostly of those with
established disease—as it is expected in the routine clinical
practice, LDAwas used in the statistical analyses. In AS, LDA
was defined as Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) of ≤2.0, and a BASDAI>4 indicated a high
disease activity. The patient was regarded to be in LDA if the
disease activity remained low on at least two subsequent
visits, while a relapse was considered when the disease activ-
ity became high from low or moderate activity at the previous
visit. The number of previous biologics used and the cortico-
steroid and traditional DMARD therapy were recorded in
every patient.
The statistical difference between various patient sub-
groups, including those with relapse after the discontinuation
of the biologic or without, was calculated with two-sample t
test or chi-square test, depending on whether continuous or
categorical variables were assessed. Correlations between cer-
tain parameters, e.g. the duration of LDA, and continuous
variables (e.g. age, duration of the disease or the biological
therapy, DAS28, etc.) were analysed with Pearson’s test. The
data are presented as mean±SD or mean (range) as appropri-
ate, and a p<0.05 value was considered statistically
significant.
Results
The reasons for the discontinuation of the biological therapy
are depicted in Fig. 1. As it can be seen, in 78 cases (45%), the
decision was necessitated by significant adverse events or the
emergence of contraindications that were deemed by the
treating physician to preclude the further use of these types
of immunosuppressive therapies. In further 45 cases (30 %),
the decision of stopping the biologic was made in agreement
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with the patient because of long-standing remission and fam-
ily planning or when the desired benefits of the treatment were
not achieved (inefficacy). Most of these latter cases had been
treated with multiple biologics, and in some of them (espe-
cially in AS patients), the origin of the complaint has been re-
considered in the light of the clinical course. In the remaining
patients, the reason for the cessation was poor compliance or
miscellaneous other causes.
In the follow-up population, the data on the biological
therapy are to be seen in Table 1. Most of the patients had
established RA or AS, and the biological therapy had been
administered for several months or years in the majority of the
cohort. Switch from one agent to another was common. At the
time of the discontinuation, the disease activity was low or
moderate in the great majority of the RA patients, whereas it
was high or moderate in most of the AS patients.
In the RA patients, after a mean follow-up of 22 months,
the disease activity was found to be low in 27 patients
(33.3 %), moderate in 37 (45.7 %) and high in the remaining
17 (20.9 %) at the time of the analysis (Fig. 2). Twenty of the
33 patients (60.6 %) in whom the biologic was stopped during
LDA have maintained this low activity for an average of
16 months (3–48). Relapse, defined as the increase of disease
activity to DAS28>5.1, occurred only in five patients
(15.1 %) after an average of 15 months after the cessation.
Consequently, RA was of moderate activity in the remaining
patients. The 20 patients with sustained low disease activity
are on the following medication: traditional DMARD mono-
therapy (50 %), low-dose corticosteroid monotherapy (20 %),
the combination of the two (20 %) and no therapy at all
(10 %).
We then sought for the identification of potential associates
of sustained LDA. The duration of LDA displayed an inverse
correlation with the disease activity measured at the time of
the stopping of biologics and—somewhat surprisingly—also
with the duration of the biological therapy (p<0.05). Similar-
ly, the occurrence of a relapse was associated with the disease
activity at cessation: in those without relapse, the DAS28 was
3.3±1.3 in contrast to 4.2±1.1 in the relapsers (p<0.05),
whereas there was a relationship of borderline statistical sig-
nificance between the duration of the biological treatment
(18.5±16.1 months in the non-relapsers vs 26.3±19.3 months
in the relapsers, p=0.08). In contrast, we have not found any
association between the occurrence of a relapse or the duration
of LDA and the age of the patients, the ACPA or RF status, the
DMARD or corticosteroid treatment after the discontinuation
and the reason for the stopping of the biologic, and we also
failed to demonstrate an association with the time between the
diagnosis of RA and the initiation of biological therapy (i.e.
“early” vs “delayed” initiation of the biologic).
In six RA patients, the cessation of the biological therapy
was specifically decided because of long-term remission. In
all of the patients, the remission has remained sustained during
the whole follow-up: its duration is 17, 37 and 55 months in
three patients who take traditional DMARDs, 7 and 19months
in two patients on traditional DMARDs and low-dose corti-
costeroid and 3 months in one patient who is completely drug
free.
In the AS patients, only three (17.6 %) had inactive disease
at the time of the discontinuation of the biological therapy,
whereas in five (29.4 %), disease activity was moderate, and
adverse event (n=32)
infection (n=25)
tumour (n=21)
remission (n=18)
family planning (n=7)
inefficacy (n=28)
poor compliance (n=27)
miscellaneous (n=17)
Fig. 1 The distribution of the causes leading to discontinuation of
biological therapy. More precise definition of the causes can be found
in the “Methods” section
Table 1 Characteristics of the
patients in the follow-up cohort
For the definition of disease ac-
tivity ranges refer to the
“Methods” section. Data are
expressed as mean (range) unless
otherwise indicated
LDA low disease activity
RA patients AS patients
(n=81) (n=17)
Disease duration since diagnosis (months) 180 (32–612) 186 (9–396)
Duration of the biological therapy (months) 20 (1–60) 13 (0.5–39)
Percentage of patients with at least one switch of biologics 44.4 41.1
Disease activity at the time of discontinuation
(DAS28 for RA and BASDAI for AS)
3.76 (1.5–6.8) 4.05 (1.0–8.7)
Percentages of patients with LDA at the time of the
discontinuation
40.7 17.6
Percentages of patients with moderate disease activity at the
time of the discontinuation
52.1 29.4
Percentages of patients with high disease activity at the time
of the discontinuation
17.2 52.9
Clin Rheumatol
in nine of them (52.9 %), AS was active. After the subsequent
follow-up of an average of 20 months, the percentages of
patients with inactive, moderately active and active disease
have become 11.7 % (n=2), 35.2 % (n=6) and 52.9 % (n=9),
respectively. Relapse occurred in four of the eight patients in
whom the biologic had been stopped at BASDAI<4.0 after a
mean of 6 months (3–9). The two patients who are currently in
remission (BASDAI<2.0) have had an inactive disease for 41
and 2 months. After the stopping of the biologics,
sulfasalazine has been administered to two patients, while
the remaining patients do not receive any DMARD. Probably
due to the low number of patients in remission, we failed to
identify any factor that may be predictive of a favourable
disease course after the cessation of the biological therapy.
Discussion
Important issues of rheumatology currently and in the near
future are to more precisely determine the optimal duration of
biological therapies, to identify the causes that lead to the
discontinuation of these treatments and to explore the predic-
tors of a favourable disease outcome after the stopping of
biologics, i.e. long-term remission without functional and
radiographic progression. As our knowledge in these ques-
tions is limited, this study may add useful information about
the natural course of RA, AS and PsA from the daily clinical
practice to the results of prospective studies with fixed proto-
cols. It is important that the three centres that participate in this
project strictly adhere to the current European guidelines for
the treatment of inflammatory arthritides and follow similar
treatment strategies.
After an average treatment duration of 20 months (RA
patients) or 13 months (AS patients), in 13.7 % and 9.3 % of
the patients, respectively, biologics were permanently
discontinued. The most common causes of the cessation were
adverse events that were considered by the treating physician
to have a high likelihood of recurrence and to have a chronic
course, or the re-introduction of the same or other biologic
would be associated with inacceptable risks. The second larg-
est subgroup comprised patients in whom the biologic was
deliberately stopped after the joint decision of the physician
and the patients. In 10 % of the patients, long-term remission
was the reason of the cessation, and although this is a signif-
icant proportion of the cohort, it reflects that a decision of
stopping the biological therapies in patients with long-
standing remission is not yet part of the routine clinical prac-
tice, similar to the international trends.
Our follow-up results indicate that the LDA is feasible in a
significant proportion of patients: more than 30 % of those
with RA had inactive disease at an average of 22 months after
the biological therapy had been stopped. In AS, however, the
risk of the recurrence of high disease activity is much higher,
and only 11.7 % of the patients remained in remission. RA
patients had a higher chance of maintaining the LDA and a
lower risk of a relapse of the disease if they had low DAS28
when the biologic was stopped. As much as 60.6 % of those
RA patients who had LDA at discontinuation as compared
with 30% of the whole cohort remained in LDA. These results
indicate that considering the discontinuation of a biological
therapy may be a realistic option in many of the RA
patients who have entered into remission or at least
LDA.
Only few prospective studies have addressed the issue of
the discontinuation of a biologic treatment. In the first such
study, the TNF20 examination, 10 recent-onset RA patients
were followed up after the cessation of infliximab therapy
administered for 1 year [4]. Nine of these patients went into
remission during anti-TNF treatment, and seven of them
remained so after a follow-up of 1 year. The largest study in
this regard so far, the BeSt trial, has follow-up data of more
than 5 years available [5]. This study compared four treatment
strategies with a strict dose escalation and tapering protocol.
Of the 120 patients who were randomized to receive
infliximab+methotrexate, 77 achieved a sustained remission,
and infliximab was subsequently withdrawn. In 43 patients
(56 %), remission has persisted thereafter during an average of
7.2 years of follow-up [5] without radiographic progression
for several years [6]. In the OPTIMA study, early RA patients
(average symptom duration, 3.9 months) had been treated
with adalimumab+methotrexate and were subsequently ran-
domized to receive either methotrexate+placebo or metho-
trexate+adalimumab [7]. In 66 % of those in whom the
adalimumab had been withdrawn, the remission persisted on
methotrexate monotherapy. In addition to these studies on RA
patients with short disease duration, two studies included
patients with established RA: the RRR trial results revealed
that 55 % of the patients preserved the LDA after 1 year after
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Fig. 2 The change in the numbers of rheumatoid arthritis patients with
high, moderate or low disease activity after the discontinuation of the
biological therapy
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the cessation of infliximab [8], whereas interim analysis of the
HONOR examination indicates that 73 % of the patients
remained in LDA 6 months after the discontinuation of
adalimumab [9]. Factors that were suitable to predict the
maintenance of LDA or remission were low disease activity
at cessation (HONOR, RRR), less functional impairment as
reflected by a low HAQ-DI index (OPTIMA), shorter disease
duration before the initiation of anti-TNF therapy (RRR, BeSt,
Chimenti et al. [10]), younger age (RRR), less radiographic
damage (RRR) and the absence of ACPA (BeSt). Our results
confirm the importance of maintaining a low disease activity
before the cessation of biologics could be considered.
Another feature that has proven to be significantly associ-
ated with a subsequent relapse-free disease course in our study
was a shorter duration of biological therapy. This seems
surprising, but one potential explanation is that these patients
may have a relatively milder disease that had responded better
or faster to biological therapy than those who needed longer
biological treatment and still relapsed after the cessation. The
previously cited studies also indicate that 6 or 12 months
of anti-TNF treatment is sufficient for the appropriate
patients to maintain the LDA after its cessation, provid-
ed that it had resulted in an effective control of the
disease.
We have even less evidence regarding the biologic-free
disease course in AS, but our experience is in accord with
the published results in that it is much less likely for an AS
patient to remain in inactive disease after an anti-TNF treat-
ment is stopped. In the study of Baraliakos et al., 90.5% of the
patients relapsed until the 36th week after the withdrawal of
the biologic, and in 24 %, the relapse has occurred as early as
before the 12th week [11]. Brandt et al. have found that all the
AS patients whose etanercept therapy had resulted in complete
remission have relapsed by the 24th week after its withdrawal
[12]. It is not known at present whether a subgroup of AS
patients may exist in whom the long-term withdrawal of anti-
TNF therapy may be feasible, and some investigators have,
therefore, aimed at examining the effects of dose reduction
instead of complete drug withdrawal, with promising results
[13], although this strategy is also far from being well
explored.
In summary, with a goal-steered therapeutic strategy, the
discontinuation of biological therapies is likely to be possible
in a relatively large proportion of RA patients. Our results and
others indicate that an established remission is a pre-requisite
for the successful withdrawal of the biologics; furthermore,
earlier diagnosis and treatment initiation, and a resulting better
functional status and less radiographic damage also carry a
better prognosis of a biologic-free remission.
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